Ligand Pharmaceuticals Incorporated
LGND
$193.03
-$2.07-1.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 2,319.50% | 111.42% | -36.55% | -333.46% | 86.18% |
| Total Depreciation and Amortization | 13.12% | -2.58% | -3.69% | -4.08% | 1.59% |
| Total Amortization of Deferred Charges | 72.44% | -24.05% | -4.85% | 5.09% | 17.83% |
| Total Other Non-Cash Items | -1,320.72% | -35.47% | -65.90% | 43.55% | -57.59% |
| Change in Net Operating Assets | -72.01% | -19.41% | -144.54% | 62.93% | 193.57% |
| Cash from Operations | -17.15% | 162.09% | -189.37% | -22.06% | 174.37% |
| Capital Expenditure | 92.99% | 0.00% | 69.94% | -19.46% | -46.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,281.13% | -304.64% | 113.47% | 17.43% | 15.53% |
| Cash from Investing | -3,213.44% | -317.96% | 112.67% | 16.95% | 15.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,617,842.86% | 0.00% | -16.67% | 40.00% | -150.00% |
| Issuance of Common Stock | 212.44% | 95.14% | -92.52% | 1.90% | 480.24% |
| Repurchase of Common Stock | -10,395.86% | 98.37% | -359.48% | -1,448.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 658.22% | 9,829.58% | 99.79% | -16,160.95% | -268.42% |
| Cash from Financing | 2,631.88% | 415.88% | -123.28% | -62.98% | 480.34% |
| Foreign Exchange rate Adjustments | -117.45% | 116.64% | 168.35% | -510.61% | -- |
| Miscellaneous Cash Flow Adjustments | 202.85% | -3,411.54% | -- | -- | -- |
| Net Change in Cash | 264.36% | 180.93% | -379.90% | -80.90% | 242.33% |